news

Cannabinoid screening reveals anti-tumour properties of CBC and CBG

2.2K
SHARES

A high-throughput screening test of different cannabinoids has demonstrated that CBC and CBG exhibit anti-tumour effects.

CBC and CBG nest to cannabis leaf

A series of high-throughput screening (HTS) tests has revealed that the cannabinoids cannabichromene (CBC) and cannabigerol (CBG) both exhibit anti-tumour properties.

Using gastrointestinal cancer cells, researchers from Cannabics Pharmaceuticals screened the necrotic effects of a variety of cannabinoids on these cancer cells, as well as other cancer types previously tested.

Both CBC and CBG were shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

Dr Yaakov Waksman, the company’s head of cannabidiol research, said: “My working assumption is that these results show that a correlation may exist between a cannabinoid’s topological polar surface area (TPSA) value and its ability to induce anti-tumour activity, diminishing cancer cell’s viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell’s membrane, whereas their acidic form (CBCA and CBGA) – do not. This could explain the difference in anti-tumour activity rates demonstrated.”

Dr Eyal Ballan, CTO and Co-Founder, commented: “We are intrigued by the results we have obtained in the lab and our aim is to consider placing an emphasis on this organ system and to further explore the differential anti-tumour properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”

Leave a Reply

Your email address will not be published. Required fields are marked *